August 19, 2025

Bedtime Cyclobenzaprine Relieves Fibromyalgia: Randomized Trial

Researchers found bedtime sublingual cyclobenzaprine reduced pain versus placebo and improved sleep, fatigue, and function with mostly mild oral adverse events.

Conexiant

August 15, 2025

FDA Approves Non-Opioid Fibromyalgia Therapy

Tonmya reduces fibromyalgia pain versus placebo in phase 3 trials, offering a non-opioid option with a generally well-tolerated safety profile.

Conexiant

August 11, 2025

FDA Approves Ketamine Product for Surgical Pain Management

PharmaTher has received FDA approval for KETARx, a ketamine therapy for surgical pain management.

Conexiant

August 11, 2025

Why Turning 26 Jeopardizes Health Coverage

A growing number of young Americans lose affordable health insurance at age 26, facing complex Affordable Care Act marketplaces, rising costs, and limited coverage options.

KFF Health News

August 06, 2025

New Preventive Option Approved for Pediatric Migraine

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.

Conexiant

August 04, 2025

Beta-HPV–Driven SCC Resolved After TCR Signaling Correction

Case study shows cutaneous squamous cell carcinoma linked to beta-human papillomavirus cleared following T-cell immune restoration.

Conexiant

July 31, 2025

FDA Approves Implantable Device for RA

“The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases."

Conexiant

July 31, 2025

‘Victim-Blaming’ in Public Health?

As Trump’s health officials push personal responsibility, critics warn their rhetoric blames patients, shapes policy, and risks deepening health inequalities.

KFF Health News

December 11, 2024

ALS Drug Misses Trial Goals

A mid-stage trial for an experimental drug in ALS patients did not meet its main goal, with patients showing more gastrointestinal upset compared to a placebo, and differing death rates between groups. Results will be presented next year, and a long-term extension study will continue.

Reuters